Clinical Trials Logo

Malignant Tumor clinical trials

View clinical trials related to Malignant Tumor.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05965843 Not yet recruiting - Healthy Clinical Trials

Intervention, Prognosis and Mechanism of Covid-19 Infection in Patients With Underlying Diseases

Start date: August 2023
Phase:
Study type: Observational

The goal of this observational study is to explore the influence of Covid-19 infection and risk factors of severe outcomes in vulnerable population including patients with chronic liver disease, malignant tumor, autoimmune disease, medical staff. The main questions it aims to answer are: 1. The clinical characteristics of vulnerable population after Covid-19 infection. 2. Risk factors for severe illness in vulnerable groups after infection with the Covid-19. 3. The impact of Covid-19 infection on the progression of underlying diseases. Information of participants will be collected such as gender, age, underlying diseases, medication status, vaccination status, clinical and biochemical indicators. Researchers will compare the mild and severe outcomes after Covid-19 infection to identify the "truly vulnerable" population and explore the potential mechanism and intervention for these population.

NCT ID: NCT05616195 Not yet recruiting - Malignant Tumor Clinical Trials

Application of 3D Printed Prosthesis in Limb Salvage Surgery for Bone Tumors

Start date: December 28, 2024
Phase:
Study type: Observational

To report the patients who underwent 3D-printed bone prosthesis replacement in Henan Cancer Hospital in the next 10 years, and collect the postoperative complications and limb function of these patients.

NCT ID: NCT05616182 Not yet recruiting - Malignant Tumor Clinical Trials

Application of LARS Ligament in Bone Prosthesis Replacement

Start date: December 30, 2024
Phase:
Study type: Observational

This is a single-center, prospective, real-world observational study designed to enroll all patients eligible for enrollment. Basic data, treatment methods, postoperative complications and limb function were collected. The differences in postoperative complications, postoperative limb function and so on between patients who underwent LARS ligament implantation and bone prosthesis replacement (ligament group) and patients who underwent bone prosthesis replacement (control group) were compared.

NCT ID: NCT05598827 Not yet recruiting - Chemotherapy Clinical Trials

Application of Douyin in Patients With Bone and Soft Tissue Malignant Tumors During Perichemotherapy

Start date: December 28, 2024
Phase: N/A
Study type: Interventional

A total of 90 patients with bone and soft tissue malignancies who planned to receive chemotherapy were enrolled in this study in Henan Cancer Hospital. They were divided into experimental group and control group for anxiety and depression value 24 hours before chemotherapy, anxiety and depression value on the day of chemotherapy, anxiety value and depression value 24 hours after chemotherapy. To evaluate the effects of watching Tik Tok on perichemotherapy anxiety and depression in patients with bone and soft tissue malignant tumors who were to receive chemotherapy, and to evaluate the effects of watching Tik Tok on the incidence of chemotherapy-related complications in patients with bone and soft tissue malignant tumors who were to receive chemotherapy.

NCT ID: NCT04237337 Not yet recruiting - Multiple Sclerosis Clinical Trials

Drugs for the Treatment of Multiple Sclerosis and Risk of Cancer: a Pharmacovigilance Analysis in Vigibase

PVSEPK
Start date: January 2020
Phase:
Study type: Observational

Even though the therapeutic panel for multiple sclerosis (MS) treatment has improved in the last 20 years, safety data especially for the second-line and innovative treatments are lacking. The association between MS and cancer has long been investigated but has led to conflicting results. No studies have reported an increased risk of cancer after long-term exposure to immuno-modulators. The present study will assess whether drugs for the treatment of MS are associated with an increased risk of cancer by analyzing the disproportionality of reports in the World Health Organization (WHO) pharmacovigilance database.